Inhibition of the enzyme dipeptidyl peptidase-IV (DPP-IV; EC 3.4.14.5) has potential in the prevention of diseases related to the development of metabolic syndrome including type-2 diabetes, heart health and obesity. Here, DPP4 is linked to obesity disorder.